H
istamine is an established endothelium-dependent vasodilator. There are numerous sources of histamine in the vasculature. In addition to histamine from circulating blood and vascular endothelial cells, histamine can be released locally from subendothelial mast cells [1] [2] [3] and adventitial mast cells 4, 5 in coronary arteries. Moreover, histamine can also derive from activated platelets, 6 T lymphocytes, and monocytes/macrophages. 7 By occupying H 1 receptors on endothelial cells, histamine activates endothelial nitric oxide synthase (eNOS). 8 The nitric oxide (NO) produced by eNOS dilates all kinds of blood vessels, including human coronary arteries, 9 and has protective effects against platelet and leukocyte adhesion and smooth muscle proliferation and, thus, probably atherosclerosis. 10 However, the direct activation of eNOS by histamine represents a short-term and probably transient action of the amine. Therefore, the present study was designed to investigate the potential long-term effects of histamine on eNOS gene expression and the ensuing changes in enzyme activity. The results show that under normal, healthy conditions, histamine can upregulate eNOS gene expression, resulting in increased NO production. This would suggest an indirect vasoprotective role for histamine.
However, there is evidence for pro-atherogenic effects of histamine. For example, histamine enhances the expression of adhesion molecules in vascular endothelial cells, thereby augmenting leukocyte-endothelial cell interactions, [11] [12] [13] an important onset event in atherogenesis. Histamine has also been shown to increase smooth muscle cell proliferation and migration, 6 and it has been implicated in intimal thickening and atherogenesis. 14, 15 In animal models, antihistamines provided protection against intimal thickening and the development of atherosclerosis. 14 In conditions of oxidative stress and atherosclerosis, eNOS can "uncouple" and become dysfunctional. A relative lack of (6R)-5,6,7,8-tetrahydro-L-biopterin due to oxidation seems to play a crucial pathophysiological role for eNOS dysfunction. 16 The dysfunctional eNOS generates superoxide from its oxygenase domain instead of NO by dissociation of the ferrous-dioxygen complex. 16 Therefore, in the present study, we also tested the functional consequences of a histamineinduced upregulation of eNOS under conditions of exogenous oxidative stress.
Methods

Cell Culture
Human umbilical vein endothelial cells (HUVECs, isolated by collagenase digestion) and HUVEC-derived EA.hy 926 cells (kindly provided by Dr Cora-Jean Edgell, Chapel Hill, NC) were cultured as previously described. 17 HUVECs from passages 3 to 5 were used.
RNase Protection Assay for eNOS mRNA Analyses
Confluent HUVECs and EA.hy 926 cells were incubated with histamine, and total RNA was isolated. The expression of eNOS mRNA was analyzed by an RNase protection assay, as described previously. 17 
Reverse-Transcriptase Polymerase Chain Reaction for Analysis of Histamine Receptor Expression
Reverse transcriptase polymerase chain reaction (RT-PCR) was performed using total RNA from HUVECs, EA.hy 926 cells, and human heart, brain, and ileum tissues as templates. Primers were designed to distinguish human H 1 , H 2 , and H 3 subtypes. The primers were TCTCTCTTTTCTGT-GGGTTATTCC (sense) and CAGCTTAATTTCTGAGAAGGAAGG-(antisense) for H 1 , ATACCACCTCTAAGTGCAAAGTCC (sense) and GATGGCTTCTAACACCTCATTGAT (antisense) for H 2 , and CTGA-CT-ACTGGTACGAAACCTCCT (sense) and CTCCTCAGCAATTTT-GTCTCTCTT (antisense) for H 3 . The sizes of the 3 RT-PCR products were 259 bp, 311 bp, and 244 bp, respectively.
Electron Microscopic Immunocytochemistry
After treatment with histamine, EA.hy 926 cells were collected by trypsin digestion. The cells were then concentrated by centrifugation, fixed, and embedded in London Resin White. Ultrathin sections were prepared ,and post-embedding immunolabeling was performed using a rabbit polyclonal anti-eNOS antibody (BD Biosciences Pharmingen, San Diego, Calif) and a gold-labeled anti-rabbit secondary antibody (10-nm particles, Sigma, St Louis, Mo). The ultrathin sections were then analyzed with an energy-filtering transmission electron microscope, as previously described. 18 The density of gold particles was determined in 20 sections and in 20 frames of 1 m 2 in each section.
Transient Transfection and Reporter Gene Assay for the Analysis of eNOS Promoter Activity
Promoter activity was analyzed by reporter gene assay using the plasmid pGl 3 -eNOS-Hu-1600 transiently transfected into EA.hy 926 cells. The plasmid contains a 1.6-kb human eNOS promoter fragment (Ϫ1600 to 23) cloned before the luciferase gene of pGl 3 -Basic, as described elsewhere. 17 Assay of Ca 2؉ /Calmodulin-Dependent Kinase II Activity Ca 2ϩ /calmodulin-dependent kinase II (CaMK II) activity was assayed using the SignaTect system (Promega). Briefly, 2.5 g of total protein samples from EA.hy 926 cells were incubated at 30°C for 2 minutes in the presence of [␥- 32 P]ATP with a biotinylated peptide, which is a selective substrate for CaMK II. The reaction was then spotted onto a streptavidin-coated SAM-Biotin-Capture membrane. The membrane was washed, dried, and exposed to x-ray film.
Determination of Total NO Synthesis as Nitrite/Nitrate and Measurement of Bioactive NO
Oxidation products of NO (NOx, ie, NO 2 Ϫ and NO 3 Ϫ ) were assayed in the supernatant of EA.hy 926 cells as a measure of total NO synthesis using a NOA 280 NO Analyzer. 19 Bioactive NO produced by EA.hy 926 cells was assayed using rat fetal lung fibroblast (RFL-6) as reporter cells. 19 
Measurement of Intracellular Reactive Oxygen Species
The determination of intracellular oxidative formation was based on the oxidation of 5-(and-6)-chloromethyl-2Ј,7Ј-dichlorodihydrofluorescein diacetate (CM-H 2 DCFDA) to yield an intracellular-trapped fluorescent compound. Fluorescence was measured in a FluoroCount Reader (Packard Bioscience). 19 After 24 hours of pretreatment with 1 mol/L histamine, the cells were washed, and intracellular reactive oxygen species (ROS) formation was assayed in the presence of 10 mol/L A23187, because superoxide/ROS generation from eNOS is a Ca 2ϩ -dependent process. 20 Other cells were exposed to oxidative stress (after the 24-hour histamine pretreatment) by a 1-hour incubation with xanthine (200 mol/L)/xanthine oxidase (5 mU/mL), either alone or in combination with 1 mmol/L N G -nitro-L-arginine methyl ester (L-NAME). Then, the cells were washed several times to remove the xanthine/xanthine oxidase, and ROS production was assayed in the presence of 10 mol/L A23187 for 1 hour.
Statistics
Statistical differences between mean values were determined by ANOVA followed by Fisher's protected least-significant-difference test for comparison of different means. 
Results
Histamine Upregulates eNOS mRNA Expression in Human Endothelial Cells in a Concentration
Histamine-Induced eNOS Upregulation Is Prevented by an Inhibitor of CaMK II, But Not by Inhibitors of Protein Kinase C, Janus Kinase 2 (JAK2), Mitogen-Activated Protein Kinases, or Phosphatidylinositol-3-Kinase
The specific inhibitor of CaMK II, KN-93, completely abolished the eNOS induction by histamine ( Figure 4A ). The , and phosphatidylinositol-3-kinase (10 mol/L LY 294002) had no effect on histamine-induced eNOS expression (3 experiments each; data not shown). A previous study demonstrated that CaMK II is also involved in H 2 O 2 -induced eNOS expression, a pathway that also requires the tyrosine kinase JAK2. 21 However, the JAK2 inhibitor, AG 490, and other tyrosine kinase inhibitors did not affect histamine-induced eNOS expression, thus indicating that JAK2 is not involved.
Histamine Activates CaMK II in EA.hy 926 Cells
Incubation of EA.hy 926 cells with histamine led to the activation of CaMK II. The CaMK II-specific phosphorylation was increased after histamine treatment ( Figure 4B ). This activation was maintained between 5 minutes and 3 hours ( Figure 4B ). Preincubation with KN-93 (3 mol/L, 1 hour) reduced the basal activity of CaMK II and completely abolished the activating effect of histamine ( Figure 4B ).
Histamine Upregulates eNOS Protein Expression in EA.hy 926 Cells
In addition, eNOS protein expression was increased in EA.hy 926 cells by histamine, as determined by electron microscopic immunocytochemistry. The histamine-treated cells showed an increased intracellular eNOS staining ( Figure 5 ).
Short-and Long-Term Effects of Histamine on NO Production in EA.hy 926 Cells Under Normal Conditions
After 24 hours of treatment of EA.hy 926 cells with 1 mol/L histamine, the cumulative NO production (determined as NOx in the culture supernatant) increased almost 4-fold ( Figure 6A ). When histamine was present only during the last hour of the 24-hour incubation, the increase in NOx was only Ϸ2-fold. After washout, EA.hy 926 cells were stimulated with 10 mol/L Ca 2ϩ ionophore A23187 for 1 hour. An increase in NOx was only seen in those cells that had been pretreated with histamine for 24 hours ( Figure 6A ). These results were confirmed with a different method, the RFL-6 reporter cell assay. This assay demonstrated that EA.hy 926 cells whose eNOS had been upregulated by histamine (24 hours of pretreatment) showed an increased production of bioactive NO on stimulation with the Ca 2ϩ ionophore A23187 ( Figure 6B ). 
Li et al eNOS Induction by Histamine
Histamine-Induced eNOS Produces ROS Under Conditions of Oxidative Stress
The treatment of EA.hy 926 cells with 1 mol/L histamine for 24 hours under normal cell culture conditions did not increase ROS generation ( Figure 7A ). However, when the cells were preexposed to oxidative stress (1-hour treatment with xanthine/xanthine oxidase), a significant increase in ROS formation was observed in cells pretreated with histamine ( Figure 7B ). This increase was prevented by the NOS inhibitor L-NAME, indicating that eNOS contributed to ROS production under these conditions.
Discussion
The present study demonstrates that histamine upregulated eNOS mRNA and protein expression in HUVECs and HUVEC-derived EA.hy 926 cells (Figures 1 and 5) .
Results from RT-PCR using subtype-specific primers indicated that H 1 and H 2 were expressed in HUVECs and EA.hy 926 cells (Figure 2A ). However, the selective H 2 antagonist cimetidine had no effect on histamine-induced eNOS expression, indicating that the H 2 receptor is not involved in eNOS upregulation. Moreover, H 2 receptors signal through adenylyl cyclase and cAMP, and our previous work has demonstrated that cAMP analogs do not affect eNOS expression in EA.hy 926 cells. 17 Thus, the histamine-induced eNOS expression in human endothelial cells is probably mediated by the H 1 receptor, because (1) eNOS induction was prevented by the selective H 1 -antagonist mepyramine ( Figure 2B ) and (2) the selective H 1 agonist HTMT upregulated eNOS expression.
The histamine-induced eNOS expression is likely a transcriptional event. Histamine increased the activity of the 1.6-kb human eNOS promoter fragment in HUVECs and EA.hy 926 cells (Figure 3) . In good agreement with mRNA expression data, activation of the eNOS promoter was blocked by mepyramine, indicating that the transcriptional activation is mediated through the H 1 receptor.
H 1 receptor stimulation results in an activation of phospholipase C and the production of inositol-1,4,5-trisphosphate, which in turn releases Ca 2ϩ from inositol-1,4,5-trisphosphate-sensitive stores. Increases in intracellular free Ca 2ϩ , [Ca 2ϩ ] i , in response to histamine, have been demonstrated for EA.hy 926 cells, 22 as well as HUVECs. 8 In human endothelial cells, the Ca 2ϩ -sensitive target responsible for the histamine-induced eNOS expression seems to be CaMK II, a ubiquitous enzyme that is also present in vascular endothelial cells. 23 The histamine-induced eNOS expression was completely abolished by KN-93, a specific inhibitor of CaMK II ( Figure 4A ), whereas the inactive analog of KN-93, KN-92, was without effect ( Figure 4A ). Histamine treatment of EA.hy 926 cells led to activation of CaMK II, which was sensitive to KN-93 ( Figure 4B ). Also in HUVECs, histamine activated CaMK II. 23 These data indicate that the histamine-induced eNOS expression involves CaMK II.
An upregulation of eNOS gene expression could result in a sustained enhancement of NO production in addition to the known short-term and transient effect of histamine on eNOS activity. Stimulation of EA.hy 926 cells with histamine for 1 hour resulted in an Ϸ2-fold increase in NOx ( Figure 6A ). This likely reflects the short-term activation of eNOS by histamine. If, however, the cells were treated with histamine for 24 hours, the increase of accumulative NOx was Ϸ4-fold. Agonist-stimulated eNOS enzyme activation is usually transient, and the enzyme activity returns to control levels within 30 minutes. 23 Thus, the cumulative NO released from endothelial cells during 24 hours is likely to consist of 2 components: short-term NO release due to eNOS activation and a persistent NO release, probably resulting from increased eNOS expression. Indeed, when the cells were washed and then stimulated with Ca 2ϩ ionophore, increased NO production was only seen in cells pretreated with histamine for 24 hours, not in those treated for 1 hour ( Figure 6A ). In agreement with this, bioactive NO, as measured by RFL-6 reporter cell assay, was increased after 24 hours of treatment with histamine ( Figure 6B ). Thus, under normal conditions and even at the early stages of vascular disease, the histamine-induced eNOS expression may represent a vasoprotective factor.
However, advanced stages of vascular diseases (atherosclerosis, diabetes, and hypertension) are associated with endothelial dysfunction and oxidative stress. In the present study, we tried to mimic these conditions by exposing endothelial cells to xanthine/xanthine oxidase. Under these conditions, the eNOS upregulated by histamine indeed contributed to ROS production ( Figure 7 ) and, thus, may enhance the preexisting oxidative stress. We have previously reported similar phenomena in animals with experimental diabetes and hypertension. 16, 24, 25 In all of these cases, the NO bioavailability decreased despite an upregulation of eNOS.
Decreased NO bioavailability can also contribute to histamine-induced coronary vasospasm. Under conditions of dysfunctional eNOS, the histamine-induced vasorelaxation is converted into a contraction, which is mediated via H 1 receptors on smooth muscle cells. 9, 26 Histamine-induced vasoconstriction has also been observed in atherosclerotic coronary arteries 26 -28 and may contribute to the onset of an acute coronary syndrome. Interestingly, an increased histamine content has been found in atherosclerotic coronary segments. 5, 27, 29 In conclusion, the present study demonstrates a novel effect of histamine on endothelial NO production. In addition to its short-term and transient action on eNOS activity, histamine also possesses a long-term effect on eNOS expression. The effect is H 1 receptor-dependent and CaMK IImediated. This eNOS upregulation may be protective under normal conditions by increasing NO production, but it may become harmful under conditions of oxidative stress when eNOS produces ROS at the expense of NO. Contribution of histamine-induced eNOS to the production of ROS after exposure of endothelial cells to oxidative stress. EA.hy 926 cells were left untreated (control, Co) or were pretreated with 1 mol/L histamine for 24 hours (His). Then, the cells were washed, and intracellular ROS formation was assayed by CM-H 2 DCFDA oxidation-based fluorescence in the presence of 10 mol/L A23187 (A). Other cells were exposed to oxidative stress using xanthine (200 mol/L) and xanthine oxidase (5 mU/mL) (XXO) for 1 hour (the 25th hour) after the 24-hour histamine pretreatment. A subgroup of cells received 1 mmol/L L-NAME together with XXO (B). After the incubation, the cells were washed several times to remove the XXO. Then, ROS production was assayed in the presence of 10 mol/L A23187. Columns represent the meanϮSEM of 3 experiments (**PϽ0.01).
